Novartis India has ended FY02 on an encouraging note. While sales represent a 7% rise, net profit has grown at a faster pace thanks to a rise in operating margins, lower interest cost and positive impact from the closure of the loss making Ciba Vision operations. A sustained rise in margins for all the four quarters of the current year was ensured on the back of better price realisations, control over input costs and re-launch of its key brands.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares (eoy) (m)
Diluted Earnings per share*
P/E (at current price)
Operating margins for the year would have been higher but for Rs 47 m incurred on VRS and Rs 23 m provided for on account of change in accounting policy for gratuity. Further, other expenditure included Rs 16.6 m provision towards dimunition in the value of investments in US 64. But for these, operating margins would have been 15.7% for FY02, a rise of 350 basis points. Other income however, includes Rs 169 m on account of profit on sale of property at Goregaon.
% of sales
Purchase of finished goods
"Pharma sales for the period closed at Rs 2,678 m registering a growth of 7.4% over the previous period. Growth was impacted by lower sales of the company’s transplant and oncology range of products.
In late 2001, the company has carved out the Biochemie segment from the existing pharma business to align the portfolio with that of the parent company. The Biochemie sector primarily focuses on the therapeutic segments of Anti-TB, Anti-DUB (gynaecology) Anti-histamines, Antibiotics, Anti-ulcerants, Anti-diabetes and Cardiovascular. This sector registered sales of Rs 1,220 m which were almost at the same level as prior year sales. On a like to like basis (pharma and Biochemie division consolidated), the company has grown 5%, underperforming industry growth rates due to absence of new products. "
Consumer Healthcare achieved 11% growth over last year largely driven by its popular OTC brand Calcium Sandoz. An encouraging growth in animal health care business was primarily driven by intensive marketing efforts in cattle and poultry segments and addition of three new licenced-in products in the cattle segment.
Table Showing Segmentwise operating margins
Sales (Rs m)
Animal Healthcare Business
*- Profit before interest and tax
At the current market price of Rs 276, the stock trades at 14x its FY02 earnings. The stock is likely to see upside due to attractive forward valuations. We expect the margins of the company to improve further, both due to good performance of its key products and further, restructuring benefits. However, dependence on imports and growth in pharma business, remain key areas of concern.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407